Literature DB >> 9396481

New look to an old symptom: angina pectoris.

F Crea1, A Gaspardone.   

Abstract

At the turn of this century, it was proposed that ischemic cardiac pain might be related to distension of the ventricular wall ("mechanical hypothesis"). Three decades later, it was hypothesized that ischemic pain might be elicited by the intramyocardial release of pain-producing substances induced by ischemia ("chemical hypothesis"). Studies carried out in the past 10 years have given strong support to the chemical hypothesis, because they have consistently shown that adenosine is a mediator of ischemic cardiac pain. Adenosine-induced ischemic cardiac pain is mediated primarily by stimulation of A1 receptors located in cardiac nerve endings and is potentiated by substance P. Conversely, the magnitude and rate of left ventricular dilation during ischemia do not predict the severity of angina. It is worth noting, however, that stretching of epicardial coronary arteries appears to potentiate the severity of angina caused by myocardial ischemia. The nervous activity generated by myocardial ischemia is modulated in intrinsic cardiac, mediastinal, and thoracic ganglia. Then it is further modulated in the central nervous system and projects bilaterally to the cortex, as demonstrated in humans by positron emission tomography, where it is decoded as a painful sensation. The causes responsible for the lack of angina during myocardial ischemia are probably different in patients who present both pain-free and painful myocardial ischemia, in patients with predominantly painless ischemia, and in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396481     DOI: 10.1161/01.cir.96.10.3766

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  Metabolic therapy for heart disease: impact of trimetazidine.

Authors:  Hani N Sabbah; William C Stanley
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

2.  Silent myocardial ischemia: Current perspectives and future directions.

Authors:  Amany H Ahmed; Kj Shankar; Hossein Eftekhari; Ms Munir; Jillian Robertson; Alan Brewer; Igor V Stupin; S Ward Casscells
Journal:  Exp Clin Cardiol       Date:  2007

3.  Ambulatory and silent myocardial ischemia in women with coronary microvascular dysfunction: Results from the Cardiac Autonomic Nervous System study (CANS).

Authors:  Rajasree Roy; Haider Aldiwani; Navid Darouian; Shilpa Sharma; Tina Torbati; Janet Wei; Michael D Nelson; Chrisandra Shufelt; Margo B Minissian; Lian Li; C Noel Bairey Merz; Puja K Mehta
Journal:  Int J Cardiol       Date:  2020-04-19       Impact factor: 4.039

Review 4.  Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Dimitrios V Moysidis; Christos Tsagkaris; Stavros P Papadakos; Alexandra Bekiaridou; Athanasios Samaras; Efstratios Karagiannidis; Marios Papadakis; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2022-03-14       Impact factor: 9.951

Review 5.  A pathophysiological compass to personalize antianginal drug treatment.

Authors:  Edoardo Bertero; Gerd Heusch; Thomas Münzel; Christoph Maack
Journal:  Nat Rev Cardiol       Date:  2021-07-07       Impact factor: 32.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.